Dexasone
Primary Central Nervous System Lymphoma
Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Allison Winter
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07608731CT.gov Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas | — | Not Yet Recruiting | — | — | — |
NCT07185373CT.gov Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | — | Not Yet Recruiting | — | — | — |
NCT06931652CT.gov Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab | — | Recruiting | — | — | — |
NCT07082868CT.gov A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) | — | Recruiting | — | — | — |
NCT05351593CT.gov Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | — | Recruiting | — | — | — |
NCT05518383CT.gov B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 | — | Recruiting | — | — | — |
NCT05036577CT.gov A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL | — | Active Not Recruiting | — | — | — |
NCT04938297CT.gov Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma | — | Unknown | — | — | — |
NCT04129710CT.gov A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) | — | Unknown | — | — | — |
NCT04083066CT.gov Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | — | Unknown | — | — | — |
Show 12 more trialsShow fewer
NCT03964090CT.gov Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | — | Active Not Recruiting | — | — | — |
NCT03495960CT.gov Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System | — | Completed | — | — | — |
NCT03703167CT.gov Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL) | — | Completed | — | — | — |
NCT03212807CT.gov Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL | — | Withdrawn | — | — | — |
NCT05274139CT.gov Treatment of Primary CNS Lymphoma ( FTD ) | — | Completed | — | — | — |
NCT03392714CT.gov Bendamustine-based Combination Therapy for PCNSL | — | Unknown | — | — | — |
NCT02203526CT.gov Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01722305CT.gov Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma | — | Completed | — | — | — |
NCT01960192CT.gov Treatment of Primary CNS Lymphoma | — | Unknown | — | — | — |
NCT02657785CT.gov Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | — | Recruiting | — | — | — |
NCT02836158CT.gov Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | — | Recruiting | — | — | — |
NCT01083342CT.gov High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Central Nervous System Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | Allison Winter | Approved | BB · 69 |
| Etoposide | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BBB |
| (+)-Vincristine | Ono Pharmaceutical Co., Ltd. | P4 | BBB |
| Methotrexate | Assistance Publique Hopitaux De Marseille | P4 | BB |
| Adriamycin | Juan P. Alderuccio, MD | P4 | BB |
| Idarubicin | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | P4 | BB |
| Orelabrutinib | The First Affiliated Hospital with Nanjing Medical University | P3 | BB |
| Cytarabine | The Lymphoma Academic Research Organisation | P4 | BB |
| Rituximab | Ono Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Primary Central Nervous System Lymphoma cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Dexasone in Primary Central Nervous System Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/dexasone-primary-central-nervous-system-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →